At the news
? BULLISHIMPACT 8/10 8-K filed Mar 5, 2026 at 07:48 ET
CorMedix reported strong Q4 2025 financial results with $128.6 million in revenue, driven by DefenCath and the recent Melinta acquisition, and achieved full-year revenue of $311.7 million ($401.3 million pro forma). The company posted net income of $163.0 million and reiterated 2026 guidance of $300-$320 million in revenue and $100-$125 million in adjusted EBITDA, while announcing a $75 million share repurchase program.
- Q4 2025 revenue was $128.6 million, up from $31.2 million in Q4 2024
- Full-year 2025 revenue was $311.7 million, with pro forma revenue of $401.3 million
- Q4 2025 net income was $14.0 million; full-year net income was $163.0 million
- Adjusted EBITDA for Q4 2025 was $77.2 million, up from $15.3 million in Q4 2024
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access